CompletedNCT05029401
A Study of Oral Ibogaine in Opioid Withdrawal
Medication studyAges 18–55United KingdomAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Manchester and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: April 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 116
- Sponsor
- atai Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05029401
- Official title
Show the full official title
Ibogaine to Determine Maximum Tolerated Dose (MTD) or Treat-to-Target Dose (TTD) for the Evaluation of Efficacy and Safety
Get this study by email
Recruitment & locations
CompletedManchester · London
Questions about this study
Who is behind this study?
The study sponsor is atai Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including DMX-1002 and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
A phase II, randomised, double-blind, placebo- controlled, multi-site, parallel group clinical trial to examine ketamine as a pharmacological treatment for alcohol dependence in an alcohol dependen...
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand